↓ Skip to main content

New generation antipsychotics for first episode schizophrenia

Overview of attention for article published in Cochrane database of systematic reviews, October 2003
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

policy
1 policy source
twitter
8 X users
weibo
1 weibo user
facebook
1 Facebook page

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
151 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
New generation antipsychotics for first episode schizophrenia
Published in
Cochrane database of systematic reviews, October 2003
DOI 10.1002/14651858.cd004410
Pubmed ID
Authors

Johannes Hamann, Werner Kissling, Stefan Leucht, Christine Rummel‐Kluge

Abstract

The new generation antipsychotics are associated with a lower risk of adverse effects compared with drugs such as haloperidol. Many treatment guidelines recommend the use of new generation ('atypical') antipsychotic drugs for people with a first episode of schizophrenia.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 151 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Chile 1 <1%
United States 1 <1%
Canada 1 <1%
Unknown 148 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 22 15%
Student > Master 19 13%
Student > Ph. D. Student 16 11%
Other 13 9%
Student > Bachelor 11 7%
Other 35 23%
Unknown 35 23%
Readers by discipline Count As %
Medicine and Dentistry 51 34%
Psychology 25 17%
Nursing and Health Professions 11 7%
Pharmacology, Toxicology and Pharmaceutical Science 5 3%
Social Sciences 4 3%
Other 9 6%
Unknown 46 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 November 2021.
All research outputs
#4,280,278
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#6,558
of 11,499 outputs
Outputs of similar age
#8,257
of 56,332 outputs
Outputs of similar age from Cochrane database of systematic reviews
#15
of 37 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 56,332 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.